CCM
KZIA

Corsair Capital Management’s Kazia Therapeutics KZIA Stock Holding History

Corsair Capital Management’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-70,000
Closed -$470K – 171
2025
Q4 		$470K Buy
+70,000
New +$597K 0.07% 104

Other funds holding KZIA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Corsair Capital Management's KZIA Position: Q1 2026 in Review

Corsair Capital Management sold out of Kazia Therapeutics (KZIA) in Q1 2026, closing a stake of 70,000 shares — an estimated $470K sold.

Corsair Capital Management first reported a position in KZIA in Q4 2025 and held it in 1 quarter. The position peaked at $470K in Q4 2025. 23 funds tracked by Wall St. Rank hold KZIA as of Q1 2026.

  • Corsair Capital Management reported no remaining Kazia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Corsair Capital Management sold 70,000 Kazia Therapeutics shares in Q1 2026, an estimated $470K.
  • Corsair Capital Management first reported a position in Kazia Therapeutics in Q4 2025 and held it in 1 quarter.
  • Corsair Capital Management's Kazia Therapeutics position peaked at $470K in Q4 2025.
  • 23 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2026.

Based on Corsair Capital Management's 13F filing for Q1 2026, filed 15 May 2026.